Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
MGI Pharma
Bloomington / Minneapolis area, Minnesota, United Statesmgipharma.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
MGI Pharma was a commercial-stage oncology and acute care biopharmaceutical company with a portfolio including approved drugs such as palonosetron hydrochloride ("Aloxi"), decitabine ("Dacogen"), and polifeprosan 20 with carmustine implant ("Gliadel Wafer"). The company also had pipeline assets targeting cancer and other indications. It was acquired by Eisai in early 2008 for $3.9 billion.
- Therapeutic areas
- HematologyNeurologyOncologyImmunology
- Modalities
- Small moleculeBiologic
- Industry
- Biotech
02
Partnerships
Collaborated with partners to reach international markets but no specific major partnerships listed in available sources.Acquired Zycos for pipeline expansion.Licensed or co-marketed some drugs.
Beyond the preview
Go deeper on MGI Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MGI Pharma.